Scopus
YÖKSİS DOI Eşleşti
SJR Q1
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results from the Phase 3 Randomized Controlled COURAGE Trial
Journal of Urology · Kasım 2024
YÖKSİS Kayıtları
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
Journal of Urology · 2024 SCI-Expanded
Doç. Dr. EMRE ALTINTAŞ →
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
Journal of Urology · 2024 SCI-Expanded
Doç. Dr. EMRE ALTINTAŞ →
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
Journal of Urology · 2024 SCI-Expanded
Doç. Dr. MURAT GÜL →
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
Journal of Urology · 2024 SCI-Expanded
Doç. Dr. ALİ FURKAN BATUR →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 3 kaydı bulundu.
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 3 kaydı bulundu.
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
2024 ISSN: 0022-5347 SCI-Expanded Q1
Doç. Dr. MURAT GÜL →
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
2024 ISSN: 0022-5347 SCI-Expanded Q1
Doç. Dr. EMRE ALTINTAŞ →
Letter: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
2024 ISSN: 0022-5347 SCI-Expanded Q1
Doç. Dr. ALİ FURKAN BATUR →
Makale Bilgileri
Dergi
Journal of Urology
Toplam Atıf
0 atıf
· Scopus
ISSN00225347
Yayın TarihiKasım 2024
Cilt / Sayfa212 · 758-759
Scopus ID2-s2.0-85200323854
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi (ISSN Eşleşmesi)
Journal of Urology
Q1
OA
SJR Skoru2,192
H-Index299
YayıncıWolters Kluwer Health
ÜlkeUnited Kingdom
Urology (Q1)